Semaglutide MASH Cost-Effectiveness Model

A 2026 US cost-effectiveness model projected that semaglutide 2.4 mg would add 1.66 quality-adjusted life years at an incremental cost of $33,031 versus standard care for non-cirrhotic MASH with moderate to advanced fibrosis. The resulting estimate was $19,911 per quality-adjusted life year gained^[1]. These are simulated lifetime outputs based on assumptions and trial inputs, not outcomes observed in a head-to-head clinical trial.

What the model was designed to answer

The analysis concerned patients with metabolic dysfunction-associated steatohepatitis, or MASH, who had moderate to advanced fibrosis without cirrhosis. It compared semaglutide 2.4 mg, resmetirom 80 mg and resmetirom 100 mg separately with standard care from a US third-party payer perspective^[2]. It did not randomize people between those three medicines.

Researchers adapted a cohort Markov state-transition model for the United States. In annual cycles, a simulated cohort could move through fibrosis stages and later liver outcomes, experience cardiometabolic complications or die. The lifetime horizon was intended to capture consequences beyond the duration directly observed in clinical trials^[3].

A model links evidence and assumptions to estimate future costs and health without observing decades of patient care. Its disease transitions, discontinuation and mortality inputs drew on published literature and trials including ESSENCE and MAESTRO-NASH. The financial frame was specific: costs were expressed in 2025 US dollars, while costs and health outcomes were discounted by 3% each year.

How to read the QALY results

In the base case, semaglutide produced 1.66 additional quality-adjusted life years, or QALYs, with $33,031 in incremental cost versus standard care. Resmetirom 80 mg produced 1.20 additional QALYs with $415,110 in incremental cost, while resmetirom 100 mg produced 1.24 additional QALYs with $245,991 in incremental cost^[1]. Every figure is a lifetime projection for the modeled cohort.

A QALY combines modeled survival and health-related quality of life into one measure; one QALY represents one year in full health, or an equivalent combination of duration and quality. That distinction matters for individual interpretation. The measure supports economic evaluation rather than promising that a patient will gain a specified number of years.

The incremental cost-effectiveness ratios were $19,911 per QALY for semaglutide, $346,810 for resmetirom 80 mg and $198,607 for resmetirom 100 mg, with each ratio calculated against standard care. At a willingness-to-pay threshold of $150,000 per QALY, semaglutide was cost effective in 99.5% of probabilistic simulations^[2]. That probability reflects uncertainty within the model and its parameter distributions. It is not a 99.5% chance that treatment benefits an individual.

Price assumptions changed the result

One scenario used a direct-to-consumer cash-price assumption of $499 per month for semaglutide 2.4 mg. Under that scenario, the model projected semaglutide to be less costly and more effective than standard care^[1]. This was a scenario input in the paper, not a guarantee of current access, insurance coverage or an individual's out-of-pocket cost.

Cost-effectiveness also depends on the perspective chosen. A third-party payer analysis includes reimbursed medical costs but excludes many patient and societal consequences, such as time away from work and unpaid caregiving. Results expressed in US dollars and US payment structures should not be transferred directly to another country or health system.

Willingness-to-pay thresholds are decision benchmarks, not treatment prices. The authors tested $50,000, $100,000 and $150,000 per QALY gained. A result below a selected threshold means the modeled health gain meets that benchmark under the inputs used. It does not mean a payer must cover the medicine or that the medicine is affordable for every patient.

The full text identifies important assumptions

The model allowed fibrosis to improve or worsen by one stage in each annual cycle, which simplifies changes that may occur differently in practice. Natural-history transitions and event risks came partly from trial populations that may not represent real-world heterogeneity. The authors also assumed that fibrosis benefits remained constant over time without waning after treatment discontinuation^[3]. That assumption may overstate long-term benefit if effects diminish.

Adverse-event effects on utility and costs were not included in the base case, potentially understating burden. Cardiovascular risks were extrapolated beyond periods observed or directly estimated in the source evidence, creating uncertainty over a lifetime horizon^[3]. Sensitivity analyses can show how results move when specified inputs vary, but they cannot test an unknown structural error or replace long-term real-world follow-up.

Readers can compare the model with the semaglutide research overview and review known adverse-effect context on the semaglutide safety page. Clinical efficacy, safety and economic value are related questions, but one does not substitute for the others.

Funding and conflicts affect interpretation

Novo Nordisk funded development of the model and manuscript. The full text states that two authors were Novo Nordisk employees and shareholders. The third author worked for a research group contracted by Novo Nordisk to develop the model and manuscript^[3]. The paper also says some data on file were not publicly available and that code was not available.

Industry funding does not make a model automatically wrong. Even so, it increases the importance of transparent assumptions, independent replication and access to inputs. Decision makers should inspect the source trials, price assumptions and structural choices rather than treating the headline ratio as a neutral fact detached from its sponsor and methods.

What we don't yet know

The model cannot establish what lifetime costs or QALYs will be in routine care. Treatment persistence, post-discontinuation effects and real-world disease transitions remain uncertain over the long term. Nor can this analysis answer whether semaglutide or resmetirom produces better outcomes when patients are randomized directly between them, because each strategy was modeled against standard care using evidence from separate programs.

Future evidence should compare projections with observed outcomes as longer follow-up accumulates, test results using independent models and examine patient or societal perspectives that capture costs omitted by the payer view. The present study supports a narrower payer hypothesis: under its US inputs and lifetime assumptions, semaglutide met commonly tested cost-effectiveness thresholds. It does not provide a treatment instruction or a personal financial forecast.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.